Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
115.97
+0.27 (+0.23%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novartis Ag ADR
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
December 21, 2023
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy...
Via
Benzinga
Exposures
Product Safety
Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside
December 20, 2023
RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis...
Via
Benzinga
(NVS) - Analyzing Novartis's Short Interest
December 20, 2023
Via
Benzinga
Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug
December 19, 2023
Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic c
Via
Benzinga
Are November’s 3 Biggest Stock Losers Worth Snapping Up Now?
December 17, 2023
The market was like an iceberg with only a few winners showing but that means there are a lot of the biggest stock losers worth getting now.
Via
InvestorPlace
(NVS) - Analyzing Novartis's Short Interest
December 01, 2023
Via
Benzinga
How Is The Market Feeling About Novartis?
November 10, 2023
Via
Benzinga
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
October 30, 2023
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
FDA Approves Merck's Drug Belzutifan For Type Of Advanced Kidney Cancer In Pretreated Cancer Patients
December 15, 2023
The FDA approved Merck & Co Inc's (NYSE: MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for adult patients with advanced renal cell carcinoma (RCC) following a...
Via
Benzinga
Exposures
Product Safety
Novartis' Newly FDA-Approved Rare Blood Disorder Drug Aces Phase 3 Study In Ultra Rare Kidney Failure Disease
December 11, 2023
Novartis AG (NYSE: NVS) announced
Via
Benzinga
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
December 10, 2023
Regulators are already on the case, and their findings will have financial impacts.
Via
The Motley Fool
Zoetis Stock A Good Companion For Your Portfolio? Shares Rising
December 07, 2023
Reflecting strong fundamentals, Zoetis stock boasts a best-possible A SMR Rating (sales+profit margins+return on equity) on an A-to-E scale.
Via
Investor's Business Daily
Novartis' Rare Blood Disorder Therapy Scores FDA Approval
December 06, 2023
The FDA approved Novartis AG's (NYSE
Via
Benzinga
Exposures
Product Safety
Novartis Hikes Its Earnings Outlook For The Third Time This Year
October 24, 2023
The company also beat third-quarter expectations after spinning off its Sandoz unit.
Via
Investor's Business Daily
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
November 29, 2023
Tuesday, the FDA said it received reports of patients developing T-cell malig
Via
Benzinga
Exposures
Product Safety
3 Healthcare Stocks to Pick Up Before the Year-End Rally
November 28, 2023
Explore the potential of healthcare stocks as the U.S. charges ahead with $4.3 trillion in healthcare spending
Via
InvestorPlace
Novartis Outlines Pure-Play Strategy Progress After Generics Business Spin-Off
November 28, 2023
Novartis AG (NYSE: NVS) has outlined the progress made in delivering its pure-play strategy, focused on four core therapeutic areas (Cardiovascular-Renal-Metabolic, Immunology, Neuroscience, Oncology),...
Via
Benzinga
Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued.
November 22, 2023
The company is working on treatments for breast cancer in a market worth $15 billion, according to the CEO.
Via
Investor's Business Daily
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
November 18, 2023
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and...
Via
Talk Markets
Diversifying Your Portfolio With Plant-Based Options
November 16, 2023
Investors see profit potential in the plant-based market due to rising consumer demand, ESG focus, and the growth of vegan products in various industries, including pharmaceuticals. However, market...
Via
Talk Markets
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On
November 16, 2023
Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.
Via
The Motley Fool
Verve Loses A Third Of Its Value As Safety Concerns Plague Its Gene-Editing Drug
November 13, 2023
Patients had big decreases in LDL cholesterol. But there were some side effects.
Via
Investor's Business Daily
3 Spectacular High-Yield Dividend Stocks to Buy in November
November 05, 2023
Income investors should find plenty to like with these stocks.
Via
The Motley Fool
Novartis' Rare Kidney Disease Candidate Aces Late-Stage Study
October 30, 2023
Novartis AG (NYSE: NVS) released topline results from the interim analysis of the ongoing pivotal Phase 3 ALIGN study of atrasentan in patients with IgA nephropathy (IgAN). IgAN is a major cause of...
Via
Benzinga
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More
October 28, 2023
The U.S.
Via
Benzinga
Exposures
Product Safety
3 No-Brainer Stocks to Buy for Under $100 Right Now
October 28, 2023
A couple of these stocks might not be available for under $100 for too much longer.
Via
The Motley Fool
2 Green Flags and 1 Red Flag for Novartis Stock
October 27, 2023
The Swiss pharmaceutical company just posted strong Q3 numbers and is going through some big changes.
Via
The Motley Fool
7 Undervalued Stocks to Buy Before Everyone Else
October 26, 2023
Buy these undervalued stocks while they trade at a significant discount compared to their intrinsic valuations.
Via
InvestorPlace
Sanofi Stock Relative Strength Rating Jumps To 84: One To Watch
October 24, 2023
Additionally, Sanofi stock has a decent 83 Composite Rating out of 99, and an 80 Earnings Per Share Rating.
Via
Investor's Business Daily
Novartis Ag (NVS) Q3 2023 Earnings Call Transcript
October 24, 2023
NVS earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.